143 related articles for article (PubMed ID: 34654653)
1. Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab.
Ksienski D; Truong PT; Croteau NS; Chan A; Sonke E; Patterson T; Clarkson M; Hackett S; Lesperance M
J Geriatr Oncol; 2022 Mar; 13(2):220-227. PubMed ID: 34654653
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
3. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab.
Ksienski D; Wai ES; Croteau NS; Freeman AT; Chan A; Fiorino L; Poonja Z; Fenton D; Patterson T; Irons S; Lesperance M
J Geriatr Oncol; 2020 Jun; 11(5):807-813. PubMed ID: 31937494
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
Ksienski D; Wai ES; Alex D; Croteau NS; Freeman AT; Chan A; Patterson T; Clarkson M; Fiorino L; Poonja Z; Fenton D; Irons S; Lesperance M
Transl Lung Cancer Res; 2021 Jan; 10(1):355-367. PubMed ID: 33569318
[TBL] [Abstract][Full Text] [Related]
5. Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort.
Ksienski D; Truong PT; Wai ES; Croteau NS; Chan A; Patterson T; Clarkson M; Hackett S; Irons S; Lesperance M
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e561-e569. PubMed ID: 34226113
[TBL] [Abstract][Full Text] [Related]
6. Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers.
Ksienski D; Truong PT; Bone JN; Egli S; Clarkson M; Patterson T; Lesperance M; Lakkunarajah S
J Geriatr Oncol; 2024 Jun; 15(5):101789. PubMed ID: 38710153
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
8. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
9. Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice.
Ksienski D; Truong PT; Croteau NS; Chan A; Sonke E; Patterson T; Clarkson M; Lesperance M
Cureus; 2021 Nov; 13(11):e19835. PubMed ID: 34963849
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.
Otsuka M; Sugihara S; Mori S; Hamada K; Sasaki Y; Yoshikawa S; Kiyohara Y
J Dermatol; 2020 Apr; 47(4):356-362. PubMed ID: 31984569
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
Cybulska-Stopa B; Pacholczak-Madej R; Kamińska-Winciorek G; Ziętek M; Czarnecka AM; Piejko K; Galus Ł; Ziółkowska B; Kieszko S; Kempa-Kamińska N; Calik J; Rolski J; Sałek-Zań A; Gajewska-Wicher K; Drosik-Kwaśniewska A; Rogala P; Kubiatowski T; Suwiński R; Mackiewicz J; Rutkowski P
Immunotherapy; 2021 Mar; 13(4):297-307. PubMed ID: 33353420
[No Abstract] [Full Text] [Related]
15. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
16. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract][Full Text] [Related]
18. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
[TBL] [Abstract][Full Text] [Related]
20. Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.
Shi S; Jaoube JA; Kanwar R; Jin MC; Amorin A; Varanasi V; Eisinger E; Thomas R; Moore JM
J Neurooncol; 2020 Jun; 148(2):291-297. PubMed ID: 32350779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
